. 2019 Oct-Dec;15(4):282–288. doi: 10.14797/mdcj-15-4-282

Table 1.

Arrhythmias associated with different cancer therapeutics.6–17,19,20,32,33,35–37,40–47

DRUG CLASS	EXAMPLE	ASSOCIATED ARRHYTHMIAS	POTENTIAL MECHANISM
Alkylating agents6	Melphalan	Atrial arrhythmias	Unknown
Anthracyclines7–9	Doxorubicin	Atrial arrhythmias	Free radical/toxin accumulation, myocardial damage/cardiomyopathy
Anthracyclines7–9	Epirubicin	Ventricular arrhythmia	Myocardial damage/cardiomyopathy, increased ventricular repolarization indices
Arsenic32,33		QT prolongation	Potassium channel inhibition
Cyclin-dependent kinase 4/6 inhibitors35	Ribociclib	QT prolongation	Unknown
Fluoropyrimidines36,37	5-fluorouracil	Ventricular arrhythmias	Secondary to coronary vasospasm/myocardial ischemia
Fluoropyrimidines36,37	Capecitabine
Immunotherapies19,20	CAR-T therapy	Atrial arrhythmias	Inflammatory like from CRS
	Checkpoint inhibitors (pembrolizumab)	Atrial/ventricular arrhythmias, bradyarrhythmias	Myocarditis/inflammatory
	Immunomodulatory agents (lenalidomide)	Atrial arrhythmias	Unknown
Platinum agents10	Cisplatin	Atrial arrhythmias	Direct myocardial irritation
Taxanes46,47	Paclitaxel	Bradyarrhythmias	Effects on histamine receptor
Tyrosine kinase inhibitors	Ibrutinib, sorafenib, sunitinib11–17	Atrial arrhythmias	PI3K pathway inhibition
	Nilotinib, sunitinib, vandetanib40–42	QT prolongation	Impaired intracellular signaling leading to enhanced late sodium and decreased potassium currents
	Ibrutinib43	Ventricular arrhythmias	Unknown
	ALK Inhibitors44,45 (crizotinib)	Bradyarrhythmias	Decrease If (funny channel) currents in sinoatrial nodal cells